-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Lexeo Therapeutics (LXEO)
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) PT Raised to $15 at H.C. Wainwright
-
-
-
-
-
-
-
Lexeo gets FDA breakthrough therapy designation for heart condition drug
-
-
-
-
-
-
-
Lexeo Therapeutics, Inc. (LXEO) Misses Q1 EPS by 10c
-
-
-
-
-
-
-
Lexeo Therapeutics (LXEO) Files $300M Mixed Shelf
-
-
-
-
-
-
-
Stifel on Lexeo Therapeutics (LXEO): 'FA-CM Data Look Promising Though Handful of Questions for 8AM Call'
-
416,850 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

